In Brief: Furness in new CDER role; Oxytrol for Women at retail; advisories on drug-tainted sex enhancers; senators want energy drink restrictions
This article was originally published in The Tan Sheet
Executive Summary
Furness takes on new CDER role; Merck’s Oxytrol OTC arrives at retail; FDA issues advisory on drug-tainted sex enhancers; senators want energy drink restrictions; more news In Brief.
You may also be interested in...
DMAA Product OxyElite Pro Named Potential Link In Acute Hepatitis Cases
FDA is investigating 29 reports of acute non-viral hepatitis in Hawaii, and the state Department of Health says 24 cases share a common link to the use of products labeled as USPlabs’ DMAA product, OxyElite Pro.
DMAA Product OxyElite Pro Named Potential Link In Acute Hepatitis Cases
FDA is investigating 29 reports of acute non-viral hepatitis in Hawaii, and the state Department of Health says 24 cases share a common link to the use of products labeled as USPlabs’ DMAA product, OxyElite Pro.
Firms Explore First-In-Class Switches With NSURE Still In Limbo
Firms are moving forward with potential first-in-class switches for chronic conditions, says Concentrics Research CEO Julie Aker. Meanwhile, FDA’s NSURE initiative offers “a lot of opportunity,” but “is still very conceptual,” the agency says.